FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 194 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer (EOC) MOST POPULAR FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer October 22, 2021 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 Research with Integrity – integrating training into research culture January 24, 2023 RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... April 18, 2023 Load more HOT NEWS Plans for NCI’s Fiscal Year 2019 Budget Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Building a Balanced Breakfast Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate...
